10-K: Adial Pharmaceuticals Focuses on US Market After Phase 3 Trial Analysis, Secures Additional Funding

Adial Pharmaceuticals is shifting its focus to the US market for its alcohol use disorder treatment, AD04, after analyzing Phase 3 trial data and securing additional funding through warrant exercises.

Summary

• Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, is developing AD04 for alcohol use disorder (AUD) treatment.
• The company completed a Phase 3 trial, ONWARD, which showed statistical significance in a pre-defined patient group of heavy drinkers, despite missing the primary endpoint.
• Post-hoc analysis of the ONWARD trial and a Phase 2b study identified specific genetic subtypes (AG+ and GG+) that showed a statistically significant response to AD04.
• Adial met with the FDA and received confirmation on the primary US endpoint, Percentage of No Heavy Drinking Days (PNHDD), and acknowledgment of the post-hoc analysis results.
• The company is now focusing on the US market and plans to conduct two additional Phase 3 trials, estimated to cost $8-12 million each, targeting the identified genetic subtypes.
• Adial has secured approximately $3.8 million in net proceeds through recent warrant exercises to support its development plans.
• The company has a worldwide, exclusive license to three patent families related to AD04, providing protection through 2031.
• Adial estimates that about one in three patients with AUD in the U.S. and Europe will have the genetic markers to indicate possible treatment with AD04.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the focus on the US market, positive feedback from the FDA, and additional funding, there are also significant risks and challenges, including the need for additional trials, the company's financial situation, and the competitive landscape. The sentiment is therefore neutral.

Positives

• The company has a clear regulatory path forward in the US based on FDA feedback.
• AD04 has shown a positive safety and tolerability profile in clinical trials.
• The companion diagnostic genetic test may enhance the likelihood of successful treatment outcomes.
• The company has a strong intellectual property portfolio with patent protection through 2031.
• Market research suggests a strong commercial opportunity for AD04 with potential for higher unit pricing than previously assumed.

Negatives

• The ONWARD trial missed its primary endpoint, requiring additional trials.
• The company has a limited operating history and has incurred significant losses since its inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company currently has no product revenues and may not generate revenue in the near future.
• The company has identified material weaknesses in its internal controls.
• The active ingredient of AD04, ondansetron, is currently available in generic form, posing a potential competitive threat.

Risks

• The company needs to secure additional financing, which may not be available on favorable terms.
• The FDA and/or EMA may not accept the planned Phase 3 endpoints for final approval of AD04.
• Clinical trials may fail to demonstrate the safety and efficacy of AD04.
• Delays in patient enrollment could impact regulatory approvals.
• The company has limited experience conducting clinical trials.
• The company is dependent on the successful development, approval, and commercialization of a genetic test.
• There is uncertainty as to market acceptance of the technology and product candidates.
• The company has limited protection for its intellectual property.
• The company may be involved in lawsuits to protect or enforce the patents of its licensors.
• The company relies on key executive officers and scientific, regulatory and medical advisors.
• The company's stock price has been volatile and may continue to be so.

Future Outlook

Adial plans to aggressively pursue FDA approval for AD04 in the US, with the understanding that US standards may translate to acceptance in other international markets. The company intends to engage a US partner to assist with funding the anticipated required clinical trials and commercialization efforts. They also plan to develop label expansions into other indications (e.g., opioid use disorder, other drug addictions, obesity, smoking cessation, eating disorders and anxiety).

Management Comments

• Based on this positive feedback received from the FDA, we have made the strategic decision to focus our efforts on the US, with the understanding that the US standards may translate to acceptance in other international markets.
• We believe that AD04 will achieve success in clinical development based on our post hoc analysis and the US FDA regulatory feedback on the pre-specified primary endpoint that the FDA has now confirmed (PNHDD).
• Market research conducted subsequent to completion of the ONWARD trial suggests unit pricing for AD04 could be significantly higher than previous assumptions which we believe confirms AD04 as an attractive commercial opportunity.

Industry Context

The document highlights the significant unmet need in the AUD therapeutic area, with a large market opportunity for an effective solution. The company's approach of using a companion diagnostic genetic test to identify patients most likely to respond to treatment is a novel approach in the field. The document also notes that current treatments for AUD have limitations, including the requirement for abstinence and significant side effects, which AD04 aims to address.

Comparison to Industry Standards

• The document mentions Alkermes and Indivior as competitors, both of which have approved drugs for AUD treatment, but these drugs require abstinence prior to treatment.
• The document notes that current treatments for AUD have limitations, including the requirement for abstinence and significant side effects, which AD04 aims to address.
• The document references a Phase 2b study conducted by the University of Virginia, which showed that a prospectively identified subgroup of alcohol-dependent individuals with specific polymorphisms of the serotonin transporter protein responded therapeutically to ondansetron administration.
• The document also references the FDA's February 2015 Draft Guidance Alcoholism: Developing Drugs for Treatment Guidance for Industry, which specifies the endpoint of reduction of heavy drinking days (PNHDD) as acceptable for approval.

Management Changes

Related Party Transactions

• The company sold the business of its wholly owned subsidiary, Purnovate, Inc., to a third party, Adovate, LLC, which was a related party at the time of the option agreement.
• The company has a license agreement with the University of Virginia Patent Foundation, where a portion of payments may be distributed to the company's Chief Medical Officer, who is also the inventor of the licensed patents.
• The company has a consulting agreement with its Chief Medical Officer, Dr. Bankole A. Johnson.
• The company has a consulting agreement with The Keswick Group, LLC, of which Tony Goodman, a director, is the founder and principal.
• The company has a shared services agreement with Adovate, Inc., in which the company holds a significant equity stake.

Stakeholder Impact

• Shareholders may experience dilution from future sales of securities.
• Employees may be affected by changes in the company's strategy and financial situation.
• Patients with AUD may benefit from a new treatment option if AD04 is approved.
• Physicians may have a new tool for treating AUD patients with specific genetic markers.
• Payers will need to consider the cost-effectiveness of AD04 compared to existing treatments.

Next Steps

• Conduct two additional Phase 3 clinical trials in parallel, targeting specific genetic subtypes.
• Conduct smaller additional studies required by the FDA, including bioavailability studies and longer-term safety data.
• Engage a U.S. partner to assist with funding the anticipated required clinical trials and commercialization efforts.
• Continue to prosecute and expand the intellectual property and product portfolio.
• Develop an extended release, once-a-day, or other modified formulation of AD04.

Key Dates

Keywords

AD04, Alcohol Use Disorder, AUD, Ondansetron, Genetic Test, Phase 3 Trial, FDA, EMA, Clinical Development, Biopharmaceutical, Addiction, Heavy Drinking, PNHDD, Serotonin, Genotype